Montanans deserve real affordability
Affordability was a defining issue of this election cycle. Montanans and Americans alike are tired of watching grocery bills, utility bills, insurance premiums and monthly prescriptions consume more of the family budget. They want prices to come down, and they deserve policies designed to make that happen.
But too many Democratic proposals confuse shifting costs with lowering costs. A subsidy can reduce the price of a favored product for one buyer while asking taxpayers to cover the difference. A price control can reduce the number on a government spreadsheet while moving the cost into premiums, taxes, reduced access or fewer choices. That is not affordability — it’s cost-shifting, and it ultimately leads to market inefficiencies that make inflation worse.
The Biden-era Inflation Reduction Act is the clearest example of this failed approach of subsidies, price controls and cost-shifting.
That should not surprise anyone. Sustained inflation is ultimately a monetary problem: too much money and credit chasing too few goods and services. Fiscal policy matters, too. When
As a case study, consider what the IRA did across prescription drug markets. It created a web of price controls and subsidies. No one should defend high drug prices, and no senior should have to choose between medicine and necessities, but the IRA’s drug-pricing provisions are not a durable affordability strategy. They rely on government-set “maximum fair prices” for selected drugs, rather than addressing the underlying reasons patients pay so much: opaque middlemen, distorted insurer incentives, limited consumer choice, and barriers to generic and biosimilar competition.
The first 10 IRA drug prices took effect this year. But the price CMS announces is not necessarily the total cost a patient experiences. Patients still confront premiums, deductibles, coinsurance, formularies and prior authorization. When
There is also a longer-term cost. Drug development requires years of research, clinical trials, manufacturing investment and risk-taking. A policy that reduces prospective returns through government price-setting can weaken incentives to develop new treatments. It can also distort the competitive markets that eventually bring generic and biosimilar prices down. The result is slower economic growth, one of the best tools we have to bring inflation down.
When it comes to prescription drugs, the answer is not to accept high prices. It is to pursue real reform: protect patients from catastrophic costs, require transparency from pharmacy benefit managers, accelerate generic and biosimilar competition, reduce regulatory barriers and give consumers more direct purchasing options.
The failures of Biden’s IRA are salient today as politicians look to fulfill the “affordability” promises they made on the campaign trail. Price controls might be a convenient way for politicians to buy votes, but they’re a horrible way to address affordability in a meaningful way.
Montanans did not vote for a bigger system of subsidies, bailouts and price controls. They voted for affordability, which means bringing down prices across the board. In the
Distributed by Newsbank, inc.


Samantha Wildow: Mercy Health warns thousands of Medical Mutual of Ohio patients may go out-of-network in 2027
BJC HealthCare, Aetna agree to extend access to care for Southern Illinois retirees
Advisor News
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
More Advisor NewsAnnuity News
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
- Jackson Launches Direct-to-Consumer Annuity Offering
More Annuity NewsHealth/Employee Benefits News
- Samantha Wildow: Mercy Health warns thousands of Medical Mutual of Ohio patients may go out-of-network in 2027
- Reports Outline Managed Care Study Results from Harvard University (Inpatient-Only List Removals Shifted Procedures To The Outpatient Setting And Reduced Medicare Spending): Managed Care
- Health and Humor: Picking a Medicare insurance plan is daunting
- Obamacare is getting more expensive in Indiana
- Hays City Commission to consider bids for health insurance, sports complex improvements
More Health/Employee Benefits NewsLife Insurance News
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- U-Haul Holding Company to Participate in Deutsche Bank Conference
- NAIC task force to address LTC riders
- Protective names Kurt Meyers Chief Legal Officer and Fernando Levy Chief Digital & AI Officer
- Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
More Life Insurance News